Posts filed under ‘Bacterias’

EDITORIAL – A new reason to reconsider that antibiotic prescription – The microbiome

Cleveland Journal of Internal Medicine December 2018 V.85 N.12

EDITORIAL – A new reason to reconsider that antibiotic prescription – The microbiome

FULL TEXT

https://www.mdedge.com/ccjm/article/189659/infectious-diseases/new-reason-reconsider-antibiotic-prescription-microbiome

PDF (CLIC en PDF)

Advertisements

January 20, 2019 at 7:59 pm

Our missing microbes: Short-term antibiotic courses have long-term consequences

Cleveland Journal of Internal Medicine December 2018 V.85 N.12

Our missing microbes: Short-term antibiotic courses have long-term consequences

FULL TEXT

https://www.mdedge.com/ccjm/article/189671/infectious-diseases/our-missing-microbes-short-term-antibiotic-courses-have-long

PDF (CLIC en PDF)

January 20, 2019 at 7:58 pm

The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae

OPEN FORUM INFECTIOUS DISEASES January 2019 V.6 N.1

Courtney L Luterbach; Ashley Boshe; Heather I Henderson; Eric Cober; Sandra S Richter

In the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant Enterobacteriaceae (CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMP-SMX. Development of resistance further limits the use of TMP-SMX in CRE infections.

FULL TEXT

https://academic.oup.com/ofid/article/6/1/ofy351/5250079

PDF (CLIC en PDF)

January 20, 2019 at 12:18 pm

Osteomyelitis Complicating Sacral Pressure Ulcers: Whether or Not to Treat With Antibiotic Therapy

Clinical Infectious Diseases January 15, 2019 V.68 N.2 P.338–342

EDITOR’S CHOICE

Darren Wong; Paul Holtom; Brad Spellberg

The treatment of osteomyelitis in patients with stage IV sacral pressure ulcers is controversial. We conducted a systematic literature review and did not find evidence of benefit of antibacterial therapy in this setting without concomitant surgical debridement and wound coverage. Furthermore, many patients with chronically exposed bone do not have evidence of osteomyelitis when biopsied, and magnetic resonance imaging may not accurately distinguish osteomyelitis from bone remodeling. The goal of therapy should be local wound care and assessment for the potential of wound closure. If the wound can be closed and osteomyelitis is present on bone biopsy, appropriate antibiotic therapy is reasonable. We find no data to support antibiotic durations of >6 weeks in this setting, and some authors recommend 2 weeks of therapy if the osteomyelitis is limited to cortical bone. If the wound will not be closed, we find no clear evidence supporting a role for antibiotic therapy.

FULL TEXT

https://academic.oup.com/cid/article/68/2/338/5050260

PDF (CLIC en PDF)

January 20, 2019 at 11:03 am

First literature review of carbapenem-resistant Providencia.

New Microbes New Infect. 2018 Jun 4;25:16-23.

Abdallah M1, Balshi A2.

Author information

1 Pharmaceutical Care Services, Riyadh, Saudi Arabia.

2 Intensive Care Unit, King Saud Medical City, Riyadh, Saudi Arabia.

Abstract

Providencia species are Gram-negative bacteria that belong to the Enterobacteriaceae family. They have intrinsic resistance to colistin and tigecycline, which makes treatment of the multidrug-resistant strains of Providencia challenging. Carbapenem-resistant Providencia species are increasingly reported. In this review, patients’ characteristics, resistance mechanisms, treatment and infection control measures of carbapenem-resistant Providencia species in the literature are described.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031241/pdf/main.pdf

 

January 18, 2019 at 9:37 am

First report of carbapenem-resistant Providencia stuartii in Saudi Arabia.

New Microbes New Infect. September 20, 2018 V.26 P.107-109.

Abdallah M1, Alhababi R2, Alqudah N3, Aldyyat B4, Alharthy A5.

Author information

1 Pharmaceutical Care Services, King Saud Medical City, Riyadh, Saudi Arabia.

2 Microbiology Department, King Saud Medical City, Riyadh, Saudi Arabia.

3 Prevention and Control of Infection Administration, King Saud Medical City, Riyadh, Saudi Arabia.

4 Pharmacy Department, Dr. Sulaiman Al Habib Hospital (As-Suwaidi), Riyadh, Saudi Arabia.

5 Intensive Care Unit, King Saud Medical City, Riyadh, Saudi Arabia.

Abstract

We present the case of 31-year-old man who developed hospital-acquired pneumonia in the intensive care unit. Pathogens were identified to be carbapenem-resistant isolates of Providencia stuartii and Klebsiella pneumoniae. The patient was treated with an extended infusion of double-dose meropenem (targeting the carbapenem-resistant P. stuartii) and colistin (targeting the carbapenem-resistant K. pneumoniae) for 2 weeks. The patient’s disease responded well to the prescribed regimen; his chest X-ray became normal, and all other signs of infection subsided. To our knowledge, this is the first description of the emergence of carbapenem-resistant P. stuartii due to AmpC hyperproduction in Saudi Arabia.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197148/pdf/main.pdf

January 18, 2019 at 9:36 am

Providencia stuartii form biofilms and floating communities of cells that display high resistance to environmental insults.

PLoS One. March 23, 2017 V.12 N.3 P.e0174213.

El Khatib M1, Tran QT2, Nasrallah C1, Lopes J1, Bolla JM3, Vivaudou M1, Pagès JM3, Colletier JP1.

Author information

1 Institut de Biologie Structurale, Université Grenoble Alpes – Commissariat à l’Énergie Atomique – Centre National de la Recherche Scientifique, Grenoble, France.

2 School of Biophysics, Jacobs University of Bremen, Bremen, Germany.

3 Équipe Transporteurs Membranaires, Chimiorésistance et Drug-Design, Université Aix-Marseille – Institut de Recherche Biomédicale des Armées, Marseille, France.

Abstract

Biofilms are organized communities of bacterial cells that are responsible for the majority of human chronic bacterial infections. Providencia stuartii is a Gram-negative biofilm-forming bacterium involved in high incidence of urinary tract infections in catheterized patients. Yet, the structuration of these biofilms, and their resistance to environmental insults remain poorly understood. Here, we report on planktonic cell growth and biofilm formation by P. stuartii, in conditions that mimic its most common pathophysiological habitat in humans, i.e. the urinary tract. We observed that, in the planktonic state, P. stuartii forms floating communities of cells, prior to attachment to a surface and subsequent adoption of the biofilm phenotype. P. stuartii planktonic and biofilm cells are remarkably resistant to calcium, magnesium and to high concentrations of urea, and show the ability to grow over a wide range of pHs. Experiments conducted on a P. stuartii strain knocked-out for the Omp-Pst2 porin sheds light on the role it plays in the early stages of growth, as well as in the adaptation to high concentration of urea and to varying pH.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363852/pdf/pone.0174213.pdf

January 18, 2019 at 9:34 am

Older Posts


Calendar

January 2019
M T W T F S S
« Dec    
 123456
78910111213
14151617181920
21222324252627
28293031  

Posts by Month

Posts by Category